Nadda Launches Indigenous Tetanus and Adult Diphtheria (Td) Vaccine to Boost Immunisation Coverage

Union Health Minister J.P. Nadda has launched an indigenously developed tetanus and adult diphtheria (Td) vaccine, marking a significant step toward strengthening India’s immunisation efforts and vaccine self-reliance.

The introduction of the locally manufactured Td vaccine is expected to enhance coverage under the national immunisation programme while reducing dependence on imported formulations. Officials said the move aligns with the government’s broader push for domestic vaccine production and public health preparedness.

Strengthening Adult Immunisation

The Td vaccine provides protection against tetanus and diphtheria, two serious bacterial infections. While tetanus can cause severe muscle spasms and life-threatening complications, diphtheria affects the respiratory system and can lead to cardiac and neurological damage if untreated.

Public health experts have emphasised the importance of adult booster doses to maintain immunity, particularly among adolescents, pregnant women, and high-risk populations.

Boost to Indigenous Manufacturing

The launch underscores India’s growing capacity in vaccine research, development, and large-scale manufacturing. Strengthening domestic production not only ensures steady supply for national needs but also positions India as a key contributor to global vaccine access.

Officials noted that indigenous production enhances quality control, affordability, and supply chain resilience.

Public Health Impact

The inclusion and rollout of the Td vaccine are expected to support ongoing efforts to eliminate vaccine-preventable diseases and improve long-term immunity across age groups.

Health authorities reiterated the importance of continued awareness campaigns and community outreach to ensure higher uptake and sustained protection.

The initiative reflects continued investment in preventive healthcare as a cornerstone of India’s public health strategy.